A new player has emerged in an effort to tackle a significant issue plaguing the pharmaceutical trade: waste caused by inadequate temperature control during transportation. Frontier Scientific Solutions, backed by $1.5 billion investment from GID, aims to revolutionize the way temperature-sensitive medications are transported across oceans.
The company's solution lies in establishing a reliable air corridor between Ireland and North Carolina, leveraging its new 530,000-square-foot warehouse at Wilmington International Airport. By flying specialized wide-body aircraft, Frontier will be able to maintain precise temperature control for steroids, vaccines, hormones, blood plasma, pharmaceuticals like GLP-1 drugs, and "active pharmaceutical ingredients."
This approach addresses the critical issue of "temperature excursions" โ preventable incidents caused by shipments exceeding safe usage limits. The company's data indicates that 60% of these occurrences happen during airport ground handling, particularly when shipments are staged on the tarmac.
To tackle this problem, Frontier has also created a foreign trade zone at Wilmington International Airport and Shannon International Airport in Ireland. By utilizing these zones, manufacturers can take advantage of reduced tariffs and streamlined customs clearance processes. The zones will allow for more efficient management of temperature-sensitive goods as tariff rates fluctuate.
The stakes are high: the pharmaceutical trade generates over $35 billion in waste each year due to inadequate temperature control. This issue affects not only the industry's bottom line but also patient safety, with compromised medications potentially leading to ineffective treatment or even harm.
Frontier Scientific Solutions is poised to transform the transportation of temperature-sensitive pharmaceuticals, offering a critical solution for manufacturers seeking to minimize waste and ensure the integrity of their products during global distribution. With its innovative approach and significant investment backing, the company aims to address this pressing issue and have a lasting impact on the industry's sustainability.
The company's solution lies in establishing a reliable air corridor between Ireland and North Carolina, leveraging its new 530,000-square-foot warehouse at Wilmington International Airport. By flying specialized wide-body aircraft, Frontier will be able to maintain precise temperature control for steroids, vaccines, hormones, blood plasma, pharmaceuticals like GLP-1 drugs, and "active pharmaceutical ingredients."
This approach addresses the critical issue of "temperature excursions" โ preventable incidents caused by shipments exceeding safe usage limits. The company's data indicates that 60% of these occurrences happen during airport ground handling, particularly when shipments are staged on the tarmac.
To tackle this problem, Frontier has also created a foreign trade zone at Wilmington International Airport and Shannon International Airport in Ireland. By utilizing these zones, manufacturers can take advantage of reduced tariffs and streamlined customs clearance processes. The zones will allow for more efficient management of temperature-sensitive goods as tariff rates fluctuate.
The stakes are high: the pharmaceutical trade generates over $35 billion in waste each year due to inadequate temperature control. This issue affects not only the industry's bottom line but also patient safety, with compromised medications potentially leading to ineffective treatment or even harm.
Frontier Scientific Solutions is poised to transform the transportation of temperature-sensitive pharmaceuticals, offering a critical solution for manufacturers seeking to minimize waste and ensure the integrity of their products during global distribution. With its innovative approach and significant investment backing, the company aims to address this pressing issue and have a lasting impact on the industry's sustainability.